Declining ALS Patients Are Waiting On The FDA...

After months of speculation and a publicized selection process befitting The Apprentice, President Trump has announced his pick to lead the Federal Reserve: former Fed Governor Kevin Warsh. Historically a monetary policy hawk, the now dovish Warsh is expected to align more closel ...  Show more

The US Senate failed to advance a government spending package on Thursday, setting up for a partial government shutdown. At the center of the debate is funding for the Department of Homeland Security. In the wake of federal agents killing two US citizens in Minnesota, the spendin ...  Show more

ALS is a disease that destroys the nerve cells in the brain and spinal cord we need for voluntary movement. There is no cure, but now there is a newly approved medication that may slow down the disease and extend patients' lives. The drug, called Relyvrio, got its start with a co ...  Show more

When the F.D.A. approved the drug Aduhelm, the first Alzheimer’s treatment to receive the agency’s endorsement in almost two decades, it gave hope to many.

But the decision was contentious; some experts say there’s not enough evidence that the treatment can address cogni ...

Aduhelm, known generically as aducanumab, is the first drug to actually affect the underlying disease process associated with Alzheimer's. Yet sales have been limited, and the drug is reaching very few patients — at least so far. It's expensive, risky and likely doing little to i ...  Show more

For decades, the law has sought to restrain nursing homes from trying to control the behavior of dementia patients with antipsychotic drugs, which are known to have adverse health effects. 

An alarming rise in schizophrenia diagnoses suggests some homes have found a way ...